Latest Management of heart failure Stories
- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus enalapril(1,2) EAST
MORRISTOWN, N.J., Nov.
AUSTIN, Texas, Sept. 26, 2014 /PRNewswire/ -- On Sept.
Dr. Milton Packer and Dr. McMurray will be presenting these results for the first time in the United States at the HFSA Annual Meeting LAS VEGAS, Sept.
- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1) EAST HANOVER, N.J., Aug.
Yesterday, on Monday, June 9, 2014, the Oklahoma Heart Hospital, and The Ohio State University implanted the United States’ first miniaturized, wireless monitoring sensors to manage heart failure
Heart failure is the second leading cause of hospitalization of Canadians over 65 and responsible for nine per cent of all deaths MONTREAL, May 29, 2014 /CNW/ - Canada's leading
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.
Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitaliization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and...
- A poem in which the author retracts something said in an earlier poem.